Citigroup set a $124.00 price objective on Eli Lilly And Co (NYSE:LLY) in a research report released on Tuesday morning. The firm currently has a hold rating on the stock.
A number of other research analysts also recently issued reports on LLY. Credit Suisse Group upgraded Eli Lilly And Co from an underperform rating to a neutral rating in a research note on Wednesday, October 31st. ValuEngine downgraded Eli Lilly And Co from a buy rating to a hold rating in a research note on Tuesday, November 6th. Societe Generale set a $106.00 price target on Eli Lilly And Co and gave the stock a hold rating in a research note on Wednesday, November 7th. TheStreet upgraded Eli Lilly And Co from a c+ rating to a b+ rating in a research note on Tuesday, November 6th. Finally, Zacks Investment Research upgraded Eli Lilly And Co from a hold rating to a buy rating and set a $128.00 price target on the stock in a research note on Wednesday, November 28th. Eleven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Eli Lilly And Co currently has an average rating of Buy and an average price target of $112.06.
Get Eli Lilly And Co alerts:LLY opened at $128.84 on Tuesday. The stock has a market capitalization of $128.39 billion, a PE ratio of 23.21, a price-to-earnings-growth ratio of 2.51 and a beta of 0.37. The company has a current ratio of 1.73, a quick ratio of 1.53 and a debt-to-equity ratio of 1.07. Eli Lilly And Co has a one year low of $74.51 and a one year high of $129.42.
Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings results on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). The firm had revenue of $6.44 billion for the quarter, compared to analysts’ expectations of $6.28 billion. Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.14 EPS. On average, research analysts expect that Eli Lilly And Co will post 5.6 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be given a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a yield of 2.00%. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. The ex-dividend date is Thursday, February 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.
In other Eli Lilly And Co news, major shareholder Lilly Endowment Inc sold 205,000 shares of the stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $122.48, for a total transaction of $25,108,400.00. Following the completion of the sale, the insider now directly owns 117,641,684 shares of the company’s stock, valued at approximately $14,408,753,456.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the stock in a transaction that occurred on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total value of $480,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 857,843 shares of company stock valued at $105,100,035 over the last ninety days. 0.11% of the stock is owned by insiders.
A number of institutional investors have recently bought and sold shares of the business. Captrust Financial Advisors lifted its holdings in shares of Eli Lilly And Co by 0.4% in the 4th quarter. Captrust Financial Advisors now owns 21,627 shares of the company’s stock valued at $2,503,000 after buying an additional 87 shares during the period. Bronfman E.L. Rothschild L.P. lifted its holdings in shares of Eli Lilly And Co by 1.6% in the 4th quarter. Bronfman E.L. Rothschild L.P. now owns 5,543 shares of the company’s stock valued at $641,000 after buying an additional 87 shares during the period. First Personal Financial Services lifted its holdings in shares of Eli Lilly And Co by 2.3% in the 4th quarter. First Personal Financial Services now owns 3,931 shares of the company’s stock valued at $455,000 after buying an additional 89 shares during the period. Carroll Financial Associates Inc. lifted its holdings in shares of Eli Lilly And Co by 1.3% in the 4th quarter. Carroll Financial Associates Inc. now owns 7,029 shares of the company’s stock valued at $810,000 after buying an additional 91 shares during the period. Finally, Bailard Inc. lifted its holdings in shares of Eli Lilly And Co by 3.6% in the 4th quarter. Bailard Inc. now owns 2,672 shares of the company’s stock valued at $309,000 after buying an additional 92 shares during the period. 75.69% of the stock is owned by institutional investors.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: No Load Funds
No comments:
Post a Comment